ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
36.52
0.72%
US Tech 100
19,803.20
-0.22%
S&P 500
5,651.77
0.36%
US Dollar vs CAD
1.3688
0.07%
Bitcoin
64,927.26
0.12%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Pasithea Therapeutics Corporation (KTTAW)

  7. Pasithea Therapeutics Corporation (KTTAW) News

KTTAW

Pasithea Therapeutics (KTTAW)

Pasithea Therapeutics Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KTTAW
DateTimeSourceHeadlineSymbolCompany
12/14/20224:17PMGlobeNewswire Inc.Majority of Stockholders Support Pasithea Directors at Special MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
12/12/20226:00AMGlobeNewswire Inc.Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac GroupNASDAQ:KTTAWPasithea Therapeutics Corporation
12/06/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society ConferenceNASDAQ:KTTAWPasithea Therapeutics Corporation
11/28/20226:05PMGlobeNewswire Inc.Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern TimeNASDAQ:KTTAWPasithea Therapeutics Corporation
10/17/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and SymposiumNASDAQ:KTTAWPasithea Therapeutics Corporation
10/12/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics Acquires AlloMek TherapeuticsNASDAQ:KTTAWPasithea Therapeutics Corporation
10/03/20225:03PMGlobeNewswire Inc.Pasithea Therapeutics to Call Special Meeting of StockholdersNASDAQ:KTTAWPasithea Therapeutics Corporation
09/20/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of DirectorsNASDAQ:KTTAWPasithea Therapeutics Corporation
09/15/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit CudkowiczNASDAQ:KTTAWPasithea Therapeutics Corporation
09/09/20229:32AMGlobeNewswire Inc.Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:KTTAWPasithea Therapeutics Corporation
08/18/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy ConferenceNASDAQ:KTTAWPasithea Therapeutics Corporation
08/11/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple SclerosisNASDAQ:KTTAWPasithea Therapeutics Corporation
08/02/20226:00AMGlobeNewswire Inc.Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group’s Unjustified CampaignNASDAQ:KTTAWPasithea Therapeutics Corporation
07/14/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics Awarded a Drug Development Research GrantNASDAQ:KTTAWPasithea Therapeutics Corporation
06/23/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and BeyondNASDAQ:KTTAWPasithea Therapeutics Corporation
06/22/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics Acquires Alpha-5 Integrin, LLCNASDAQ:KTTAWPasithea Therapeutics Corporation
04/14/20223:15PMGlobeNewswire Inc.Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022NASDAQ:KTTAWPasithea Therapeutics Corporation
03/30/20223:15PMGlobeNewswire Inc.Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022NASDAQ:KTTAWPasithea Therapeutics Corporation
03/08/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics Announces Collaboration with The Glimpse GroupNASDAQ:KTTAWPasithea Therapeutics Corporation
02/24/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022NASDAQ:KTTAWPasithea Therapeutics Corporation
02/09/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel WeinbergerNASDAQ:KTTAWPasithea Therapeutics Corporation
02/03/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple SclerosisNASDAQ:KTTAWPasithea Therapeutics Corporation
01/26/20227:00AMGlobeNewswire Inc.Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine TreatmentsNASDAQ:KTTAWPasithea Therapeutics Corporation
12/21/20217:00AMGlobeNewswire Inc.Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United KingdomNASDAQ:KTTAWPasithea Therapeutics Corporation
12/01/20217:00AMGlobeNewswire Inc.Pasithea Therapeutics Expands its Mobile Clinics into Florida and NevadaNASDAQ:KTTAWPasithea Therapeutics Corporation
11/29/20214:45PMGlobeNewswire Inc.Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq RulesNASDAQ:KTTAWPasithea Therapeutics Corporation
11/24/20217:52AMGlobeNewswire Inc.Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq RulesNASDAQ:KTTAWPasithea Therapeutics Corporation
11/23/20217:00AMGlobeNewswire Inc.Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.NASDAQ:KTTAWPasithea Therapeutics Corporation
11/17/20217:00AMGlobeNewswire Inc.Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International FootprintNASDAQ:KTTAWPasithea Therapeutics Corporation
11/11/20217:00AMGlobeNewswire Inc.Pasithea Therapeutics Collaborates with Renowned Musician and Producer to Create Soundtracks for Ketamine TherapyNASDAQ:KTTAWPasithea Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:KTTAW

Your Recent History

USOTC
AXXA
Exxe (PK)
NASDAQ
FFIE
Faraday Future Intellige...
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
WDLF
Decentral Life (PK)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
HIRU
Hiru (PK)
USOTC
ENZC
Enzolytics (PK)
NASDAQ
COOP
Mr Cooper
USOTC
IQST
iQSTEL (QX)
COIN
XRPUSD
Ripple
AMEX
SPY
SPDR S&P 500
NASDAQ
NB
NioCorp Developments
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved